Photo of { Brenna C. Carey, MS, PhD}

Brenna C. Carey, MS, PhD


  • Member, Translational Pulmonary Center
  • Member, Division of Pulmonary Biology
  • Assistant Professor, UC Department of Pediatrics

About

MS: Pharmaceutical Sciences with Specialization in Drug Development, University of Cincinnati, College of Pharmacy, Cincinnati, OH, 2010,

PhD: Molecular and Developmental Biology, University of Cincinnati, College of Medicine, Cincinnati, OH, 2003,

BS: Biology, John Carroll University, University Heights, OH, 1998,

Post-doctoral Research Fellow: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008,

Interests

Regulations, management, and coordination of clinical research trials in rare lung diseases, specifically pulmonary alveolar proteinosis (PAP); pathogenesis of PAP; developing and validating clinical research tests to diagnose PAP; evaluating several therapeutic options for individuals with PAP; translational pulmonary science; rare lung disease clinical research diagnostic testing; diagnosis of individuals with hereditary or autoimmune PAP clinical trials; National PAP Registry; inhaled GM-CSF treatment for individuals with autoimmune PAP and hereditary PAP; safety and efficacy of Pioglitazone for autoimmune PAP patients

Research Areas

Publications

DEVELOPMENT OF A DRIED SERUM ASSAY FOR THE DETECTION OF GM-CSF ANTIBODIES TO AID IN THE DIAGNOSIS OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) Thiruppathi, E; Kim, J; Djidotor, R; Ali, A; Carey, B; Trapnell, B. Chest. 2025; 168(4):a3757.

Pharmacokinetics and pharmacodynamics of inhaled molgramostim in healthy people. Trapnell, BC; Carey, BC; Robinson, BR. BMJ Open Respiratory Research. 2025; 12(1).

Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. Trapnell, BC; Inoue, Y; Bonella, F; Wang, T; Mccarthy, C; Arai, T; Akasaka, K; Mariani, F; Mogulkoc, N; Song, JW; Robinson, B; Fleming, R; Wasfi, Y; Pratt, R. New England Journal of Medicine. 2025; 393(8):764-773.

Autoimmune Pulmonary Alveolar Proteinosis: Update from the US National PAP Registry. Carey, BC; Chalk, C; Stock, J; Mccarthy, C; Wang, TS; Krischer, J; Trapnell, BC. American Journal of Respiratory and Critical Care Medicine. 2025; 211(Supplement_1):a1814-a1814.

Pulmonary hypertension during high-dose GM-CSF therapy of autoimmune pulmonary alveolar proteinosis. Ataya, A; Mitchel, S; Carey, B; Sippel, J; Mccarthy, C; Trapnell, BC. Pulmonary Circulation. 2024; 14(4):e70020.

A toxicology study of Csf2ra complementation and pulmonary macrophage transplantation therapy of hereditary PAP in mice. Arumugam, P; Carey, BC; Wikenheiser-Brokamp, KA; Krischer, J; Wessendarp, M; Shima, K; Chalk, C; Stock, J; Ma, Y; Black, D; Lowe-Daniels, D; Reeves, L; Kaiser, A; Trapnell, BC. Molecular Therapy: Methods & Clinical Development. 2024; 32(2):101213.

Disseminated nocardiosis and anti-GM-CSF antibodies. Brugnoli, B; Salvati, L; Di Lauria, N; Botta, A; Tozzetti, C; Biscarini, A; Capone, M; Ferrentino, F; Naldi, C; Ascione, G; Bartoloni, A; Annunziato, F; Parronchi, P; Palterer, B. European Journal of Clinical Microbiology and Infectious Diseases. 2024; 43(5):1003-1007.

Human inherited CCR2 deficiency underlies progressive polycystic lung disease. Neehus, A-L; Carey, B; Landekic, M; Panikulam, P; Deutsch, G; Ogishi, M; Arango-Franco, CA; Philippot, Q; Modaresi, M; Mohammadzadeh, I; Aladjidi, N; Trapnell, BC; Casanova, J-L; Bustamante, J. Cell. 2024; 187(2):390-408.e23.

Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients. Campo, I; Carey, BC; Paracchini, E; Kadija, Z; De Silvestri, A; Rodi, G; De Amici, M; Torre, C; Zorzetto, M; Griese, M; Meloni, F; Corsico, AG; Trapnell, BC; Mariani, F. European Respiratory Journal. 2024; 63(1).

A dried blood spot test for diagnosis of autoimmune pulmonary alveolar proteinosis. Carey, B; Chalk, C; Stock, J; Toth, A; Klingler, M; Greenberg, H; Uchida, K; Arumugam, P; Trapnell, BC. Journal of Immunological Methods. 2022; 511:113366.